Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Male Breast Cancer: early-phase trial registry
1 of 15 indexed Male Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 1 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Male Breast Cancer: 15 US clinical trials tracked, 1 recruiting.
Male Breast Cancer is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 5 of these trials.
Enrollment posture brief
Registry condition male-breast-cancer
OPEN 1 | RECR 7% | LATE 0 | EARLY 13 | RANK #1140 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Liver Disease (7% recruiting · 15 trials)
Male Breast Cancer lists 1 open slots (7% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Male Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Male Breast Cancer is recruiting below its size-band peers.
1 of 15 indexed trials (6.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Male Breast Cancer research.
University of Washington accounts for 5 of 15 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Male Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 15 trials that report a genuine target (sentinel values excluded). 15 of those (100%) plan for fewer than 100 participants.
-
Male Breast Cancer research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
ETHAN - ET for Male BC
Jose Pablo Leone
NCT05501704
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
NCT00513695
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
NCT00470301
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT01869764
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
NCT00028496
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT00006228
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02046421
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
University of Washington
NCT00331552
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Sanjiv Sam Gambhir
NCT01806675
Decitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00030615
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
University of Washington
NCT00791037
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
NCT00028535
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
University of Washington
NCT00425672
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
University of Washington
NCT01153672
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
University of Chicago
NCT01706432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Male Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Male Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Male Breast Cancer page
15 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Male Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Male Breast Cancer trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Male Breast Cancer condition card totals 15 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.